APA (7th ed.) Citation

Eto, M., Motzer, R., Choueiri, T., Haanen, J., Oya, M., Uemura, H., . . . Larkin, J. (2024). 280P Efficacy of avelumab + axitinib (A + Ax) vs sunitinib (S) by number of IMDC risk factors in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses from the final analysis of the phase III JAVELIN renal 101 trial. Annals of Oncology, 35, S1512. https://doi.org/10.1016/j.annonc.2024.10.300

Chicago Style (17th ed.) Citation

Eto, M., et al. "280P Efficacy of Avelumab + Axitinib (A + Ax) Vs Sunitinib (S) by Number of IMDC Risk Factors in Patients (pts) with Advanced Renal Cell Carcinoma (aRCC): Subgroup Analyses from the Final Analysis of the Phase III JAVELIN Renal 101 Trial." Annals of Oncology 35 (2024): S1512. https://doi.org/10.1016/j.annonc.2024.10.300.

MLA (9th ed.) Citation

Eto, M., et al. "280P Efficacy of Avelumab + Axitinib (A + Ax) Vs Sunitinib (S) by Number of IMDC Risk Factors in Patients (pts) with Advanced Renal Cell Carcinoma (aRCC): Subgroup Analyses from the Final Analysis of the Phase III JAVELIN Renal 101 Trial." Annals of Oncology, vol. 35, 2024, p. S1512, https://doi.org/10.1016/j.annonc.2024.10.300.